Baker Brothers latest buys and sells
39 buys and sells in Baker Brothers's latest 13F filing, largest first. The largest is the addition to RVMD, $353.6M or 1.8% of the reported portfolio.
Key facts
- Moves
- 39
- New positions
- 8
- Complete sales
- 8
- Largest move
- RVMD, $353.6M
- Latest filing
- Aug 14, 2026
From Baker Bros. Advisors's filing for (Q2 2026), filed , against the filing for Mar 31, 2026.
| # | Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|---|
| 1 | Revolution Medicines IncRVMD | ▲ Added 20% | +1.89M | $353.6M | 1.77% |
| 2 | Insmed IncINSM | ▲ Added 19% | +1.38M | $146.6M | 0.73% |
| 3 | Edgewise Therapeutics IncEWTX | ▼ Reduced 44% | −2.87M | $116.8M | 0.59% |
| 4 | Abivax SAABVX | ▼ Sold out | — | $97.5M | 0.49% |
| 5 | Summit Therapeutics IncSMMT | ▼ Reduced 9.9% | −3.61M | $52.5M | 0.26% |
| 6 | Spyre Therapeutics IncSYRE | ▼ Sold out | — | $50.4M | 0.25% |
| 7 | IDEAYA Biosciences IncIDYA | ▲ Added 27% | +1.06M | $39.6M | 0.20% |
| 8 | Faeth Therapeutics IncFTH | ▲ New | +1.29M | $32.2M | 0.16% |
| 9 | Relay Therapeutics IncRLAY | ▲ Added 144% | +1.67M | $31.2M | 0.16% |
| 10 | Centessa Pharmaceuticals PLCno ticker on file | ▼ Sold out | — | $26.6M | 0.13% |
| 11 | Immunocore Holdings plcIMCR | ▼ Sold out | — | $22.1M | 0.11% |
| 12 | Abcellera Biologics IncABCL | ▲ Added 9.0% | +2.74M | $21.5M | 0.11% |
| 13 | Celldex Therapeutics IncCLDX | ▲ Added 78% | +517.25K | $19.2M | 0.10% |
| 14 | Contineum Therapeutics IncCTNM | ▼ Sold out | — | $18.6M | 0.09% |
| 15 | argenx SEARGX | ▼ Sold out | — | $18.4M | 0.09% |
| 16 | Cytokinetics IncCYTK | ▲ New | +211.27K | $18M | 0.09% |
| 17 | Intellia Therapeutics IncNTLA | ▲ New | +930.23K | $15.7M | 0.08% |
| 18 | Immatics N.V.IMTX | ▼ Reduced 13% | −1.41M | $14.3M | 0.07% |
| 19 | Parabilis Medicines IncPBLS | ▲ New | +500K | $13.7M | 0.07% |
| 20 | Arcus Biosciences IncRCUS | ▲ Added 103% | +429.2K | $13.2M | 0.07% |
| 21 | Compass Pathways PlcCMPS | ▼ Sold out | — | $13M | 0.06% |
| 22 | Avalyn Pharma IncAVLN | ▲ New | +350K | $11.5M | 0.06% |
| 23 | Pharvaris N VPHVS | ▼ Sold out | — | $10.6M | 0.05% |
| 24 | Cerus CorpCERS | ▼ Reduced 36% | −3.61M | $10.6M | 0.05% |
| 25 | Tango Therapeutics IncTNGX | ▲ New | +333.33K | $10.4M | 0.05% |
| 26 | Avalo Therapeutics IncAVTX | ▲ New | +550K | $10.2M | 0.05% |
| 27 | Jade Biosciences IncJBIO | ▼ Reduced 25% | −410.8K | $9.1M | 0.05% |
| 28 | Viridian Therapeutics IncVRDN | ▲ Added 21% | +411.3K | $7.6M | 0.04% |
| 29 | Verastem IncVSTM | ▲ Added 327% | +1.91M | $7.3M | 0.04% |
| 30 | Roivant Sciences LtdROIV | ▼ Reduced 3.1% | −150.9K | $5.3M | 0.03% |
| 31 | Incyte CorpINCY | ▲ Added 0.06% | +18.45K | $2.1M | 0.01% |
| 32 | Design Therapeutics IncDSGN | ▲ Added 3.6% | +92.57K | $1.3M | 0.01% |
| 33 | Immunome IncIMNM | ▲ New | +55.31K | $1.2M | 0.01% |
| 34 | Immunovant IncIMVT | ▼ Reduced 0.4% | −22.92K | $883.3K | 0.00% |
| 35 | Madrigal Pharmaceuticals IncMDGL | ▲ Added 0.07% | +1.5K | $805K | 0.00% |
| 36 | Beone Medicines LtdONC | ▲ Added 0.03% | +2.64K | $752.2K | 0.00% |
| 37 | Kiniksa Pharmaceuticals InternationalKNSA | ▲ Added 0.3% | +8.48K | $542.2K | 0.00% |
| 38 | Acadia Pharmaceuticals IncACAD | ▲ Added 0.04% | +17.16K | $434.1K | 0.00% |
| 39 | Denali Therapeutics IncDNLI | ▲ Added 0.07% | +2.61K | $67.2K | 0.00% |
Questions and answers
What did Baker Brothers buy last quarter?
The largest purchases in the latest 13F filing: RVMD, $353.6M; INSM, $146.6M; IDYA, $39.6M; FTH, $32.2M; RLAY, $31.2M; ABCL, $21.5M.
What did Baker Brothers sell last quarter?
The largest sales in the latest 13F filing: EWTX, $116.8M; ABVX, $97.5M; SMMT, $52.5M; SYRE, $50.4M; Centessa Pharmaceuticals PLC, $26.6M; IMCR, $22.1M.
How is the size of a buy or sell worked out?
As the change in shares at the price the filing implies for the quarter's end (reported value divided by shares) — an estimate of the trade, not what was paid. A position sold out is sized at its value in the previous filing.
Learn
Cite this page
Funkfolio, “Baker Brothers: buys and sells, Q2 2026 13F”, data as of 14 August 2026. https://funkfolio.com/gurus/activity?investor=baker-brothers
Underlying data: SEC EDGAR, Form 13F-HR.
Source: SEC EDGAR, Form 13F-HR. A move is a change in share count between an investor's latest filing and the one before; a share split in between is allowed for where one is on record. Size is the shares bought or sold at the price the filing implies for the period end (reported value ÷ shares) — an estimate of the trade, not what was paid — and a position sold out is sized at its value in the previous filing. “Of portfolio” sets that size against the portfolio reported for the period. Only each investor's 150 largest positions and 50 largest exits are read. Filings appear up to 45 days after the quarter ends; none of this is advice.